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ABSTRACT
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous 
system with immune-mediated damage on myelinated nerve tracts. Accumulating 
evidence support a role for autoreactive T-lymphocytes orchestrating immune-
attacks on myelinating oligodendrocytes (OLs). While oligodendrocyte precur-
sor cells (OPCs) may initially compensate for loss of myelin by differentiating 
into OLs, later stages of MS are characterized by arrest of OPC differentiation 
and clinical disease progression. Reactive oxygen species (ROS) are important 
in many contexts, but their role in regulation of adaptive immune processes and 
remyelination in MS is still uncertain. 
We here first characterized the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-
activating MS-therapy dimethyl fumarate (DMF/ Tecfidera™) in cell cultures 
and an experimental model for neuroinflammation. In MS patients we assessed 
the effect of DMF on transcription and epigenetic modification in immune cells, 
as well as ROS production by monocytes. Our findings indicate that monocyte-
derived ROS is linked to the clinical efficacy of DMF by modulating the adap-
tive immune response, in turn highlighting modulation of redox processes as a 
therapeutic target in autoimmune disease.
In order to study the effect of DMF and other redox active agents, we developed a 
cell based reporter system (pTRAF) that enabled the visualization of transcription 
factor activity in real-time. Using pTRAF and other in vitro and in vivo models we 
further characterized the downstream effects of DMF and a set of more selective 
Nrf2-activating compounds. Finally, we performed extensive in vitro and in vivo 
characterization of Glutathione S-transferase 4α (Gsta4), which is regulated by 
Nrf2 and serves an important role for scavenging of the lipid peroxidation product 
4-hydroxynonenal (4-HNE). Interestingly, higher levels of Gsta4 was associated 
with faster and more complete remyelination by facilitating the differentiation of 
OPC into mature myelinating OLs. This was suggested to be mediated through 
modulation of the Fas/Casp8/Bid-axis, leading to increased survival of differen-
tiating OPCs. 
Collectively, our findings support a role for redox processes in regulating adaptive 
immune responses in MS. Furthermore, a specific redox-related process involving 
4-HNE and Gsta4 was found to regulate OPC survival during remyelination. Both 
these mechanisms may represent interesting novel therapeutic targets in MS, as 
well as in other autoimmune and demyelinating conditions. 
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ABBREVIATIONS
[-SH] thiol goup
[•OH] hydroxyl radical
[4-HNE] 4-hydroxynonenal/4-hydroxy-2-nonenal
[H2O2] hydrogen peroxide
[LOO•] lipid peroxyl radical
[O2•–] superoxide
[O2] (di)oxygen
APC antigen presenting cell
ARE anti-oxidative response element
ATP adenosine triphosphate
bFGF basic fibroblast growth factor
Bid BH3 interacting-domain death agonist
CC corpus callosum
CCR2 C-C chemokine receptor 2
CF clemastine fumarate
CNS central nervous system
DA Dark agouti
DMF dimethyl fumarate
DMT disease modulatory therapy
EAE experimental autoimmune encephalomyelitis
GCLC glutamate-cysteine ligase catalytic subunit
GCLM glutamate-cysteine ligase regulatory subunit
GFP green fluorescent protein
GLUT1 glucose transporter 1
HEK293 human embryonic kidney 293 cells
HIF hypoxia inducible factor
IFA incomplete Freud’s adjuvant
IFN-γ interferon-γ
IGF-1 insulin-like growth factor 1
Keap1 Kelch-like ECH-associated protein 1
LDH lactate dehydrogenase
LPC lysolechitin (lysophosphatidylcholine)
MBP myelin basic protein
MCT monocarboxylate transporter
MOG myelin oligodendrocyte glycoprotein
MRI magnetic resonance imaging
MS multiple sclerosis
NFκB nuclear factor κ-light-chain-enhancer of activated B cells
NOX (NADPH oxidase) nicotinamide adenine dinucleotide phosphate oxidase 
Nrf2 nuclear factor (erythroid-derived 2)-like 2 
OL oligodendrocyte
pre-OL premature oligodendrocyte
OPC oligodendrocyte precursor cell
aOPC adult oligodendrocyte precursor cell
PDGF platelet-derived growth factor
PLP myelin proteolipid protein
PPMS primary progressive multipole sclerosis
pTRAF plasmids for transcription factor reporter activation-based upon fluorescence
PUFA polyunsaturated fatty acids
qPCR quantitative polymerase chain reaction 
ROS reactive oxygen species
RRMS relapsing remitting Multiple multiple sclerosis
SNP single nucleotide polymorphism
SPMS secondary progressive Multiple multiple sclerosis
TBI (experimental) traumatic brain injury
TCA tricarboxylic acid cycle 
TH1 type 1 helper T cell
TH17 type 17 helper T cell
TNF tumor necrosis factor
Treg regulatory T cell
11 INTRODUCTION
1.1 Prologue
Myelin associated to nerve fibers was first described by Antonie van Leeuwenhoek 
(b.1632) using his latest invention, the microscope1. In 1781 Felice Gaspar Fontana 
(b.1730) further described the large number of uniform cylinders surrounding the 
nerve as “basic organic elements of nerves”. Almost 150 years later Pío del Río-
Hortega (b.1882) named them oligodendroglia and suggested that it to be the cell 
type producing myelin. Betty Geren (b.1922) together with Mary Bunge (b.1941) 
and Richard Bunge (b.1932), all pioneers in electron microscopy, confirmed 
Hortega’s observation with their caption of myelin sheaths from an oligodendrocyte 
wrapped around a transected axon. This discovery was made nearly three centuries 
after van Leeuwenhoek´s initial discovery using his much simpler microscope.
In the image, you can see a phagocytic cell maybe interacting with a myelinated 
and transected axon.
21.2 Redox regulation
Reactive oxygen species (ROS) are small chemically reactive oxygen-derived 
molecules that may be derived from multiple sources, including: mitochondria, 
NADPH oxidases, lipoxygenases and peroxidases.
Oxidative stress is the term for incapacity to sufficiently scavenge ROS in a biologi-
cal system. Unless scavenged ROS avidly reacts chemically and non-specifically 
with surroundings biomolecules, such as nucleic acids, carbohydrates, lipids and 
proteins, which may cause irreversible damage and loss of function. During the 
interaction between ROS and surrounding biomolecules of the cell, electrons (e–) 
are transferred from donor to acceptor compound. Compounds that donate e– are 
reductants and compounds that take up e– are oxidants. Fundamental physics state 
that reductants and oxidants always coexist since an e– cannot be generated or 
destroyed; a coexistence that can be referred to as redox. 
Multiple transcription factors are engaged during redox regulation in health and 
disease2–5.
The primary defense against oxidative stress is orchestrated in a delicate fashion by 
the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2). Nrf2 is 
kept in the cytoplasm by the oxidative stress sensitive Kelch-like ECH-associated 
protein 1 (Keap1) in complex with Cul3 E3 ligase6 (Fig.1). In the absence of 
 oxidative stress Keap1 captures Nrf2 in the cytosol, where it is continuously 
ubiquitinated and subsequently degraded in the proteasome7. In the presence of 
oxidative stress, the thiol-containing (-SH) Keap1 is oxidized, undergoes confor-
mational change and dissociates from Nrf28,9. Nrf2 will then be able to translocate 
to the cell nucleus and dimerize with different members of the small Maf protein 
family and bind to anti-oxidative response elements (ARE)8,9. The Nrf2-Maf 
 hetero dimers are able to regulate the expression of about 200 transcripts6,7,10–12. These 
transcripts largely belong to two pathways: the thioredoxin and the glutathione 
system, together essential to maintain redox homeostasis and to prevent oxidative 
stress13–15. Key-players in the thioredoxin system are thioredoxin and thioredoxin 
reductase. Glutamate-cysteine ligase regulatory subunit (GCLM) and glutamate-
cysteine ligase catalytic subunit (GCLC) generate one of the main antioxidants, 
namely the non-protein thiol glutathione (GSH) and accordingly belongs to the 
glutathione system. Both systems are overlapping, since knock-out experiments 
have illustrated that both pathways adapt to compensate for the loss of the other16. 
However, disruption of both pathways is associated with a lethal phenotype17.
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Figure 1. Illustration of Nrf2 signaling pathway.
1.21 Mitochondrial ROS in the brain
Mitochondria play an essential role in supplying eukaryotic cells with energy via 
adenosine triphosphate (ATP) generated from oxygen (O2). In addition, mito-
chondria serve important roles for Ca2+-buffering, iron storage and apoptosis18,19. 
ROS generated from mitochondria (also referred to as mROS) can be regarded as 
a by-product of redox processes, where it is estimated that during the conversion 
of O2 to ATP 2–5% is instead converted into ROS. This is sometimes referred to 
as leaky mitochondria20. The generation of ATP from oxygen in the mitochondria 
is essential for cells and thus requires extensive control to be maintained. In addi-
tion, due to the reactive nature of ROS intermediates, all processes must be tightly 
controlled to avoid by-stander damage induced by ROS and cellular elements. 
Despite mitochondria being a ubiquitous organelle, symptoms from primary mito-
chondria disorders are often related to the central nervous system (CNS), likely 
due to the high energy demand21. Thus, if focusing on mitochondria in the brain, 
Na+/K+ ATPase facilitates the transmembrane transport of sodium (export) and 
potassium (import) along the axons to maintain axonal resting potential. During 
homeostasis, 70% of the axonal mitochondria are located close to the node of 
Ranvier, where the Na+/K+ ATPases are present in myelinated axons21,22. Rapid 
shifts in cellular potential occurring during axonal signal conduction make Na+/
K+ ATPases a major energy consumer in the CNS23.
Myelination of larger axons not only facilitates proper signal transduction but 
also favor efficient use of energy (reviewed in section 1.41). 
4During homeostasis there is a variance in axonal mitochondria density between 
different CNS tracts that correlates with the level of myelination and axonal 
diameter24,25. Furthermore, several research groups have described an increase 
and redistribution of energy-dependent ion-channels in response to insufficient 
axonal insulation26,27. The loss of proper axonal insulation would thus be linked to 
increased energy demand. This notion is also supported by findings in the Shiverer 
mouse, which lacks the ability to produce sufficient myelin due to a mutation in 
the gene coding for myelin basic protein (MBP). Hence, the Shiverer mouse dis-
plays an increased mitochondrial density and higher activity of the Complex IV28. 
Similar results have been obtained in transgenic models targeting myelin prote-
olipid protein (PLP)29. In addition, an experimental model for demyelination using 
Theiler virus also displays higher mitochondria density in demyelinated compare 
to myelinated axons30. In line, mitochondrial dysfunction has been implicated also 
in a mouse model of Multiple sclerosis (MS), namely experimental autoimmune 
encephalomyelitis (EAE)31, where the application of ROS scavengers prevented 
neurodegeneration32–34. Taken together these findings suggest that cells of the CNS 
are particularly sensitive to mitochondrial dysfunction.
1.22 Generation of ROS from NOX enzymes in the periphery
Perhaps due to the early discoveries of certain ROS scavengers, such as sodium 
dismutase (SOD), ROS often were regarded as something unwanted and potentially 
toxic during homeostasis35. Over the years this view has been revised to accom-
modate the characterization of dedicated producers of ROS, such as membrane-
associated nicotinamide adenine dinucleotide phosphate oxidase (NOX/NADPH 
oxidase) that transport NADPH-derived e– across the membrane to reduce oxygen, 
O2 to superoxide, [O2•–] 18,36. In addition, NOX enzymes are expressed by a diversity 
of cells during homeostasis, thus further challenging the view that generation of 
ROS is restricted to pathological conditions37.
The NOX family consists of seven members (NOX1-5 and DOUX1-2) where 
NOX1-4 all share the subunit gp22phox but otherwise are made up by different 
subunits. 
The importance of NOX was identified in patients with chronic granulomatous 
disease. These patients showed increased susceptibility for bacterial infection 
despite that their leukocytes maintained functional phagocytic and chemotactic 
functions. However their phagocytes were not able to burst generating superoxide, 
[O2•–] and hydrogen peroxide (H2O2) to break bacterial DNA38,39. To further verify 
the role of NOX in innate immunity, deletion of NOX2 or gp22phox gave rise to a 
similar phenotype in mice38. 
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Figure 2. Illustration of all ROS intermediates. Colored labels to the right  
indicate subcellular location of the chemical reaction.
1.23 Downstream effects of ROS
ROS modulate multiple intracellular signaling pathways and cell functions both in 
the cytosol and on the cellular surface, and this has been extensively reviewed40,41. 
One example of intracellular events influenced by ROS is the interplay between 
Nrf2 and nuclear factor κ-light-chain-enhancer of activated B cells (NFκB)42,43. 
Another example is the oxidation of polyunsaturated fatty acids (PUFA) in the 
bilayer cell membrane that faces both the cytosol and the extracellular compartment 
by the ROS intermediate hydroxyl radical, [•OH]. Due to its high capability to be 
reduced, hydroxyl radical may initiate a rapid chain-like reaction with PUFA in 
the cell membrane, where the PUFAs forms lipid peroxyl radicals, [LOO•]. These 
radicals will further oxidize surrounding PUFAs of the cell membrane. This pro-
cess is referred to as lipid peroxidation (LPO) and can rapidly cause destruction 
of PUFA-rich areas, such as the cell membrane. In this regard, myelin sheaths are 
also particularly sensitive due to their high density of lipids. When reduced, lipid 
peroxyl radicals release reactive aldehydes such as 4-hydroxynonenal (4-HNE), 
malondialdehyde and acrolein44,45. These reactive aldehydes are less reactive com-
pared to ROS intermediates. To make an comparison with a ROS intermediate, 
hydroxyl radical has an estimated in vivo a half-life of 10–9 seconds46, whereas the 
half-life of 4-HNE is up to two minutes44. This implies that 4-HNE can diffuse and 
6interact with biomolecules further away from the production origin compared to 
ROS intermediates. Just as ROS, 4-HNE may interfere with multiple homeostatic 
processes47 and may bind DNA to cause proteasomal and mitochondrial dysfunc-
tion48. However, 4-HNE is restricted to form protein adducts via covalent inter-
actions only with cysteine, histidine and lysine44,49, which in turn makes certain 
protein structures more sensitive than others.
1.3 Monocyte development and subsets
Monocytes derive from granulocyte-macrophage progenitors in the bone marrow, a 
type of hematopoietic stem cell that also generates neutrophils, eosinophils, baso-
phils and dendritic cells. During homeostasis, bone marrow-derived monocytes 
accounts for ~5–10% of all leukocytes in the blood50. The monocyte population 
both in human and mouse is heterogeneous and can be further classified with 
regard to nuclear morphology and size. 
Human monocytes subsets in the circulation are mainly divided into two groups 
based on the expression of CD14, a part of the lipopolysaccharide (LPS) receptor, 
and CD16, the type III Fc-receptor γ (FcγRIII)51. A subset of monocytes, referred to 
as inflammatory monocytes (CD14hiCD16–) in addition express the C-C-chemokine 
receptor 2 (CCR2). They also displays phagocytic capacity and are able to pro-
duce significant amounts of cytokines, including tumor-necrosis  factor (TNF) and 
interleukin-650. Another subset is referred to as resident mono cytes (CD14+CD16+) 
and displays high surface expression of MHC class II molecules and FcγRII52. 
Greismann et al. identified the mouse Ly6C epitope to overlap with the human 
CCR2+ monocyte subset53,54. Based on this finding the mouse model have been 
the primary model to study functions of different monocyte subsets53,54. Thus, in 
mice inflammatory monocytes are identified by Ly6C+CCR2+CX3CR1+. Adoptive 
transfer of inflammatory monocytes expressing green fluorescent protein (GFP) 
have indicated these cells to have a lifespan of 20 hours during homeostasis55. In 
inflammatory conditions these CCR2+ monocytes migrate to the tissue where they 
upregulate CD11c and MHC class II50. Later they will also acquire T cell priming 
capacities and become antigen presenting cells (APCs)52. CCR2 is also crucial 
for the process of exiting from the bone marrow and thus Ly6C is considered to 
be primarily be expressed on newly formed monocytes in the circulation54, while 
Ly6C–CCR2–CX3CR1hi monocytes are regarded as terminally differentiated56.
In addition to Ly6C+ monocytes, recent studies have also suggested an intermediate 
Ly6C monocyte population to represent a further differentiated form of APCs57. 
This suggests that inflammatory Ly6C+ gives rise to macrophages with an iNOS 
signature whereas Ly6Cint give rise to monocyte-derived dendritic cells. 
71.31 NOX, ROS and CNS autoimmunity
The role of NOX in innate immune cells in infections is well described elsewhere 
and the focus in this section will thus focus on NOX-derived ROS in immune cell-
regulation and its potential role in conditions of CNS autoimmunity.
EAE (described in detailed in section 2.5) is the commonly used experimental 
model for MS. The EAE model reproduces important hallmark events seen in 
the early relapsing-remitting phase of MS (RRMS), including priming of T cells 
in lymphoid tissues, CNS-infiltration of encephalitogenic T cells and the appear-
ance of demyelinated lesions in the CNS. Disease activity in the EAE model is 
primarily driven by T cells, which is illustrated by the fact that adoptive transfer of 
encephalitogenic T cells is sufficient to elicit clinical disease58. In terms of numbers 
however, monocyte-derived cells are the most prominent CNS-infiltrating cells 
at the primary bout of disease59,60. The relevance of monocytes is underscored by 
the observation that rodents lacking circulating monocytes do not develop clinical 
EAE. Histological assessment of CNS-lesions also reveals the presence of NOX 
enzymes and ROS-mediated damage, suggesting also an important role for ROS 
pathways. Interestingly, generation of ROS from monocytes/monocyte-derived 
macrophages suppresses various T cell function resulting in anti-inflammatory 
outcomes61–65 (Fig.3). 
The role of monocytes in neuroinflammation is however complex, since the effects 
of circulating monocytes compared to monocytes infiltrating the tissue differ 
considerably. Thus depletion of superoxide [O2•–] production due to knock-out of 
NOX causes break of T cell tolerance66 and induction of autoimmune responses. 
Also loss of NOX further worsen autoimmune conditions39,67–69. In line with this, 
lack of ROS generation in monocytes/macrophages also increases T cell prolifera-
tion70 and during antigen presentation alter lineage commitment to generate more 
TH1, TH1771 and to lesser extent beneficial Treg72,73 (Fig.3). Interestingly, there are 
also supporting findings for a ROS-induced apoptotic-gradient among T cells 
subtypes, where the state of maturation and location appear to affect the level 
of  susceptibility to ROS-induced apoptosis. Hence, naïve T cells in the thymus 
are sensitive74, while circulating naïve T cells are not as sensitive as activated T 
cells75,76. Further, the induction of lymphocyte apoptosis depend on the intracellular 
depletion of anti-oxidative GSH where the presence of GSH prevent development 
of autoimmune responses66,77,78.
Several studies have been conducted to pin-point endogenous T cell mechanisms 
being targeted by ROS. One approach to quantify the level of oxidation has been 
made via assessment of chemically reduced thiols [-SH] on the cell surface. An 
additional approach has been to assess the abundance of intracellular GSH during 
T cell activation using CD45RA, which is highly expressed on naïve T cells but 
8downregulated upon antigen-encounter. High levels of chemically reduced cell 
surface [-SH] on T cells arise due to low levels of oxidative ROS78,79. Further, 
chemically reduced cell surface [-SH] levels are diminished on T cells following 
clonal expansion and proliferation79. Interestingly, T cell cultured with  reducing 
agents, thus increasing the presence of cell surface [-SH], attenuate the their 
responsiveness and proliferation80.
The intracellular balance in redox state also have implications on transcriptional 
activities decisive for cell phenotype and/or lineage commitment. The transcrip-
tion factors NFκB and Fork-head transcription factors of class O are both involved 
T cell homeostasis, maturation and survival and are both influenced by the intra-
cellular redox state81–83.
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Figure 3. Illustration of ROS-mediated alternations in immune  
responses and immune cell-cell interactions.
1.32 Multiple sclerosis and dimethyl fumarate
Among pathological conditions with demyelinating components, MS is the most 
well-studied. MS represents a heterogeneous, demyelinating and neurodegenerative 
condition, with genetic associations to a large number of immune-related genes, in 
particular genes related to T cell functions84–86. In addition there are also environ-
mental factors contributing to disease onset87,88. MS onset often occurs during 
the third or fourth decades of life and women are more than twice as susceptible 
as men89. Of the patients diagnosed with MS, about 80% initially present with a 
relapsing remitting disease course referred to as RRMS. These patients display 
bouts of neurological symptoms, which correlates with the infiltration of immune 
cells into the CNS90. Diagnostic hallmarks for MS and disease progression thus 
includes magnetic resonance imaging (MRI) visualizing plaques consisting of 
these infiltrating immune cells90,91. Despite large inter-individual differences, a 
9majority of patients with time will convert into a phase of unrelenting worsening; 
secondary progressive MS (SPMS). A minority of patients displays a progressive 
phenotype from start; primary progressive MS (PPMS)92. Progressive phases of MS 
are characterized by a steady decline in cognitive and neurological function largely 
independent of infiltrations of immune cells and the relapses seen in RRMS85,93.
During homeostasis, CD4+ T cells are present and patrolling the CNS. In  disease 
however, the infiltrating CD4+ T cells are reactivated by local APCs in the peri-
vascular space, which trigger them to progress into the CNS parenchyma and 
produce cytokines such as TNF and interferon-γ (IFN-γ)94. These cytokines acti-
vate surrounding microglia and perivascular macrophages causing degradation of 
the myelin sheaths. Current disease modulatory therapies (DMTs) for MS mainly 
primary target the dysfunctional adaptive immune phenotype of MS. In  particular, 
DMTs that restrict the recruitment of peripheral immune cells of the adaptive 
immune system to the CNS have been proven successful89. Examples include; S1PR 
antagonists inhibiting lymphocyte exit from the lymph nodes (fingolimod and more 
selective S1PRs), blocking of VLA-4 expressed on immune cells that prevents 
migration across the BBB (natalizumab) and DMTs that deplete specific immune 
cell populations (monoclonal anti-CD20 and anti-CD52, and cladribine) 89,95.
In contrast to these DMTs, the mechanism of action of dimethyl fumarate (DMF/
Tecfidera™) in MS, has been less clear. DMF is a first-line DMT for RRMS used 
in clinical routine in Sweden from from May 201496–98. It was originally found 
to be effective for psoriasis and was discovered by serendipity to also improve 
clinical MS symptoms in a small number of patients suffering from both condi-
tions99. Following this discovery, DMF was also shown to ameliorate clinical 
symptoms in EAE100,101. Among the suggested pathways targeted by DMF is the 
Hydroxycarboxylic acid receptor 2 in microglia102. Further, pre-clinical studies 
ascribed DMF a cytoprotective effect when used in vitro via the transcription 
factor Nrf2103–106. More recent studies verified the involvement of Nrf2107, but 
also indicated peripheral immune cells as an important target108–113. It should also 
be noted that DMF is not specific towards Nrf2114,115, and in fact may also affect 
immune cells independently of Nrf2116,117.
1.4 Juvenile and adult oligodendrocyte development
During development, the generation of oligodendrocyte precursor cells (OPC) and 
their subsequent differentiation to mature myelinating cells of the CNS is tightly 
regulated118–123. During embryonic development, three waves of OPCs propagate 
from the forebrain, progressing in a dorsal-ventral manner124,125. Studies  applying 
cell fate-mapping have shown a first wave of NK2 Homeobox 1 (Nkx2.1), Nkx2.2 
and oligodendrocyte transcription factor 2 (Olig2) positive OPCs to populate the 
whole developing telencephalon, this is initiated at embryonic day 12.5 (E12.5)126. 
10
Nkx2.1 positive OPCs are to a large extent replaced by a second wave of Gsx2 
positive OPCs initiated at E15.5, the latter wave will also persist postnatally126,127. 
At postnatal day 0 (P0), a third wave of OPC expressing Emx1 will progress 
in a dorsal-ventral pattern from the dorsal ventricular zone and first facilitate 
 myelination in the deep cortical layers and then the superficial layers128,129. This 
dorsal-ventral pattern is also preserved during remyelination129. These OPCs 
generated during development have been described to be more motile and have a 
more rapid cell-cycle compared to adult OPCs (aOPC) which are generated during 
adult life130,131. This is also the reason for the common use of OPC from neonatal 
rodents to establish primary OPC cultures132. 
Nkx2.2 and Olig2 may regulate each other and their co-existence is essential to 
enable development into oligodendrocytes (OL). Olig2 directly induces SRY-box 
10 (SOX10), a hallmark transcription factor that is essential for OL maturation and 
also exerts a positive feedback on Olig2. SOX10 interacts with several additional 
proteins to mediate OL differentiation. To date four different SOX10-mediated 
pathways of differentiation has been identified: (1) Myelin regulatory factor 
(MYRF), where SOX10 and MYRF show overlapping binding to transcriptional 
control regions close to transcripts involved in myelination; (2) Chromatin modu-
lation via CHD8 followed by expression of BRG1, which together with Olig2 
activates ZFP24 and CHD7 to regulate the onset of myelination and remyelina-
tion; (3) During onset of differentiation TCF7L2 interacts with ZBTB33 to repress 
β-catenin, which exerts a negative effect on myelination. (4) Recent work have 
also showed that dephosphorization of NFATC2, causes its activation and together 
with SOX10 prevents repression of Nkx2.2 and Olig2133,134.
In parallel to differentiation, programmed cell death is extensive during develop-
ment. Thus, in the developing rat cortex 20–30% of premyelinating oligodendro-
cytes (pre-OLs) undergo apoptosis prior to post-natal day 21 (P21)128. In the rat 
optic nerve as many as 50% of pre-OLs undergo apoptosis prior to myelination135. 
Two more recent and visually striking studies using in vivo imaging also show 
 apoptosis to occur in adult rodents136,137. The reason for this temporal susceptibility to 
apoptosis is debated. The transcription factor TFEB-PUMA-axis, highly expressed 
in pre-OLs, has recently been indicated to be involved during development138. In 
addition, the same research group has suggested that loss of the platelet-derived 
growth factor (PDGF) receptor in pre-OLs, which is highly expressed in OPC, 
makes pre-OLs more susceptible to apoptosis139. Another plausible reason, that 
has recently been illustrated is that OLs receive trophic support from axons249.
This is in line with studies showing that differentiating pre-OLs have a limited 
timeframe to make reciprocal contact with surrounding axons during develop-
ment140,141. Upon proper trophic feedback in terms of basic fibroblast growth 
 factor (bFGF), PDGF and/or insulin-like growth factor 1 (IGF-1) maturing OLs 
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will further differentiate and myelinate the naked axon119,138,142–144. During homeo-
static conditions, OPCs and OLs will generate myelin throughout life, in mice 
up to two years of age137,145. However, in the absence of proper growth signals, 
programmed cell death programs will be activated144. One additional explana-
tion for the temporal susceptibility of pre-OLs to apoptosis is suggested by the 
findings that OLs may display a maturation-dependent vulnerability to oxidative 
stress146 (molecular mechanisms reviewed in section 1.21) and thus apoptosis147. 
Regardless of cause, the programmed cell death program in OLs involves both 
activation of caspases148–151 and alternation of members of the B-cell lymphoma 2 
(Bcl-2)  family146,152–154. In summary, both OPCs and OLs seem to be dynamically 
regulated cell populations throughout the whole life.
1.41 Oligodendrocyte – form and function
OLs are essential since they provide insulation and trophic support to axons155 and 
the axonal capacity to propagate signals is dependent on factors such as axonal 
diameter, myelin thickness, internode length and the distribution of nodes of 
Ranvier156–158. As mentioned above, the brain consumes a significant amount of 
oxygen to generate energy in order to maintain axonal resting potential, which is 
reflected by the fact that the brain stands for 20% of our total oxygen consump-
tion. OLs are sensitive to ROS159 especially during differentiation146,148,160,161 and 
thus scavenging of these molecules is essential146,162–166.
During limited periods of time, the brain can generate energy via anaerobic 
 glycolysis producing pyruvate that enters the mitochondrial tricarboxylic acid cycle 
(TCA) in order to generate ATP. If not directly used by the mitochondria, lactate 
dehydrogenase (LDH) converts pyruvate to lactate for storage. Upon increased 
need of more ATP, LDH converts it back to pyruvate167,168. Lactate can also be 
directly imported to neurons via the monocarboxylate transporter 2 (MCT2)167,168. 
The glucose storage is restricted in neurons and thus neural glycolysis can only go 
on for shorter periods169. Instead the neurons have to rely on extracellular  lactate 
 supplied by adjacent and/or surrounding glia. In OLs, glucose is taken up by  glucose 
transporter 1 (GLUT1) and converted to pyruvate and lactate. However, OLs can 
also export lactate for direct uptake by adjacent or surrounding neurons170,171.
The importance of this extracellular lactate shuttling is elegantly shown by 
OL-specific monocarboxylate transporter 1 depletion causing severe axonal injury 
without damage to the OLs. Following administration of extracellular lactate the 
phenotype is reversed171. Interestingly, axonal swelling and degeneration appear 
to take place despite an intact myelin ultrastructure170–172. Instead, these studies 
suggest OL-specific loss of certain proteins involved in OL metabolic support to 
the axon as more crucial for axonal survival than the physical support from the 
myelin170–172. 
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1.42 Remyelination
Regeneration of organs and/or tissues take place even in higher mammal species 
such as humans. In the skin, superficial lesions are healed and subsequently closed. 
The same concept applies for the brain where aOPCs traditionally are  considered 
the principal source of myelinating OLs145,173–175, repopulating  demyelinated 
lesions176–179. This process, referred to as remyelination, is the fundament of proper 
regeneration of demyelinated lesions, e.g. in the context of neuro-inflammatory 
diseases such as MS.
In resemblance with skin-wounds leaving scars, remyelinated brain lesions can 
leave permanent180 shadow plaques181, first described by Lassmann et al. in 1983 
(Fig. 4). Remyelinated axons will have longer internodes and thinner myelin 
sheaths, hence a reduced myelin staining and the appearance of a “shadow”. Despite 
being thinner, the regenerated myelin protect the axon from degeneration180,182–185. 
Whether normal axonal function is preserved is more elusive. 
Previous studies has shown preserved conduction and clinical functions despite 
thinner myelin186,187. However, there are also contradicting findings where computa-
tional approaches suggest that restoration of conduction will not be complete188,189. 
In addition, indirect evidence for reduced axonal velocity could be found in patients 
with hereditary motor and sensory neuropathies, suggestively due to the thinner 
myelin observed in these patients190. Likely restored velocity and normal axonal 
function following remyelination may depend on additional factors including 
axonal diameter and may also differ between tracts. With the assumption that 
demyelination as a primary event may cause secondary alterations in the axon, 
it has been shown that remyelinated OLs have a higher density of mitochondria 
compared to myelinated OLs191. This is supported by studies describing increased 
mitochondria activity in and transport along the axon in genetically or toxin-
induced demyelination27,28,192,193. In addition, preliminary data of ours indicates a 
strong relationship between axonal mitochondria size and surrounding myeling 
sheath thickness250. However, what kind of molecular adaptions are needed in the 
axon and/or OLs to maintain sufficient axonal function following remyelination 
requires further exploration.
Based on studies conducted in rats, it is estimated that OPCs make up 3–8% of 
the total amount of CNS cells194,195 and the OPCs are found throughout the brain, 
also in and around demyelinated lesions196–198. The involvement of OPCs during 
remyelination has been illustrated using Cre-based cell-fate mapping199,200. Upon 
need of regeneration, OPCs re-enter the cell-cycle174,201–203. Due to the presence 
of OPC, a block of differentiation has been suggested as the threshold preventing 
remyelination.
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Interestingly, also other reasons explaining the relatively poor capacity to remyelinate 
in humans have been proposed204. A recent study conducted in cats and non-human 
primates showed that mature OLs can participate in remyelination205 contradicting 
what has been shown in lower species, using Cre-recombinase under the Mbp-
promoter206. Furthermore, two additional studies conducted with human cells, one 
of which combined single cell data from mice and MS patients, illustrate OLs to be 
more heterogeneous than previously expected207. The second study to some extent 
confirms that pre-existing mature OLs can contribute to remyelination due to a 
low degree of cell turn-over208. Together this underlines potential discrepancies in 
remyelination both between strains, species and experimental models.
Currently there is also a promising candidate for remyelination in clinical trials. 
Clemastine fumarate (CF) is an anti-histaminic drug identified to boost myelina-
tion in an in vitro screen209–211.
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Figure 4. Myelin and oligodendrocytes in corpus callosum. Representative images of 
Luxol fast blue stained and pseudo-colored  corpus callosum. (a) Indicates a demyelinated 
area (asterisk), (b) indicates a shadow plaque (arrow). (c) Transmission electron micro-
scopy image of transected axon with surrounding myelin and a pseudo-colored OL-branch 
myelinating an axon. Scale-bar a, b 500µm, c 1µm.
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2 METHODS
2.1 Flow cytometric measurement of ROS
Flow cytometric analyses are commonly used in the field of immunology to quantify 
chemical and physical characteristics of individual cells. This is made possible via 
fluorescent labeling of extra- and/or intracellular epitopes which upon excitation 
at the corresponding wavelength will emit fluorescent light that can be detected212. 
In Paper I flow cytometric analysis was used to quantify generation of intracellular 
ROS in CD14+ monocytes using dihydrorhodamine-123 (DHR-123)213,214. In  addition, 
proportions of monocyte subsets were also quantified108,215 (Fig. 5). 
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Figure 5. ROS generation in monocytes from MS-patients on DMF therapy. ROS  generation 
in CD14hiCD16- and CD14+CD16- monocytes before (white bars) and one month (blue 
bars) following DMF start.
2.2 Animals
In Paper IV, based on previous findings by our group216,217, a Dark agouti rat (DAWt) 
over-expressing Gsta4 under a CAG-promotor (DAGsta4) was purchased to study 
 involvement of 4-HNE load in CNS cell survival and differentiation (Fig. 6). In 
addition, DA rats expressing green fluorescence protein (DAGFP) and plain DA 
rats were used. Animals were bred in the animal facility at Karolinska University 
Hospital (Stockholm, Sweden) in a pathogen free and climate-controlled environ-
ment with regulated 12 h light/dark cycles. All experiments were approved and 
performed in accordance with Swedish National Board of Laboratory Animals and 
the European Community Council Directive. For all experiments animals at an age 
of 8–12 weeks were used. For all TBI (Section 2.3), LPC (Section 2.4) and bone 
marrow transfer in EAE experiments (Section 2.5) male animals were used. For 
regular EAE female animals were used.
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Figure 6. Resistance to intrathecally administered 4-HNE. Neurofilament light (NFL) 
levels in rat CSF 24h following intrathecal administration of 4-HNE.
2.3 Experimental traumatic brain injury model
The experimental traumatic brain injury (TBI) model used in Paper III is an open 
skull free falling weight drop model, representing a focal brain tissue injury216–219. 
There is a plethora of different experimental models for TBI generating differ-
ent types of injuries. These can be separated based on the characteristics of the 
mechanical force and if generating focal versus diffuse injury following impact with 
subsequent effects on axonal degeneration which may be more diffusely distributed 
in the tissue versus affecting certain areas 220,221. The model is characterized by an 
early infiltration of granulocytes and later activation of brain-resident microglia in 
combination with infiltrating monocytes216–219 (Fig. 7). In humans, many victims 
of TBI display both focal and diffuse injuries. The model used here, represents 
mainly a focal injury model. The anesthetized rat is placed in a stereotactic frame 
followed by craniotomy (3 mm posterior and 2.3 mm lateral of Bregma). A piston 
is resting on the exposed dura and upon impact of the weight on the piston, the 
dura is compressed 3 mm on the longitudinal axis44 (Fig. 7).
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Figure 7. Alternation in cell number following TBI in rats.
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2.4 Demyelinating lysolecithin model
Lysolecithin (lysophosphatidylcholine, LPC) is a chemical compound also present 
in low abundance in the cell membrane222,223. Upon apoptosis it partakes in the 
recruitment of phagocytes224 and it is used to study remyelination, since it effectively 
removes a majority of mature OLs225,226. There are, however, other toxin induced 
models available to study remyelination227. Advantages of using LPC or ethidium 
bromide include the instant and focal demyelination of white matter around the 
site of injection, followed by consistent remyelination, a process that has been well 
documented. In Paper IV LPC was preferred due to its limited effect on astrocytes 
compared to ethidium bromide (Fig. 8). Administration of other commonly used 
toxins, such as cuprizone, also results in immediate demyelination, but requires a 
longer exposure time and thus demyelination and remyelination will occur simul-
taneously to a larger degree compared to LPC and ethidium bromide179,227.
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Figure 8. RNAseq of corpus callosum derived O4+ OLs during naïve state and three or ten 
days following LPC administration. (a) Illustration of experimental set-up. (b) Significantly 
differentially regulated transcripts in DAWt during demyelination, remyelination and  during 
both de- and remyelination. (c) Gene ontology based on significant transcripts in b.
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LPC can be administered to different white matter tracts227 and herein we injected 
25 µL 0.1% LPC to the CC, 1.0 mm posterior and 1.2 mm lateral of Bregma and 
2.2 mm ventral of the skull bone. 
2.5 Bone marrow transplantation and experimental 
autoimmune encephalomyelitis
In Paper IV we used a MS-like disease model, EAE. To a large extent our  knowledge 
in MS, especially concerning cell trafficking and activation in the target tissue, is 
based on findings from EAE94. In rats, EAE is achieved by subcutaneous immu-
nization with myelin oligodendrocyte glycoprotein (MOG) in a mixture with 
incomplete Freud’s adjuvant (IFA). The adjuvant is necessary for the proper expo-
sure of MOG to the local APC, which will migrate to local draining lymph nodes 
and present MOG-antigens to naïve CD4+ T cells. These cells will then leave the 
lymph nodes and migrate to the CNS. The EAE model mimics several important 
features of the early relapsing-remitting disease phase of MS , however there 
are also limitations. This includes the need for active immunization, the lack of 
Fe2+ and oxidized phospholipids accumulation in CNS tissue seen in human, and 
absence of accumulation of oxidized phospholipids in active lesions. Also, active 
MS lesion pathology and EAE differ to a large extent in terms of gene expression 
of mitochondrial genes228.
To study pathological processes in the spinal cord during EAE independently of 
genotype of the bone marrow derived immune cells we lethally irradiated  animals 
and transplanted them with DAGFP hematopoietic stem cells to repopulate the bone 
marrow. 
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3 AIMS
The overall aim of this thesis was to understand the various role of ROS and ROS-
related biomolecules in different cells in demyelinating conditions. 
Paper I
To characterize immune cell number, functionality, transcription and epigenetic 
changes following treatment with the DMF, targeting Nrf2 in RRMS patients.
Paper II
To develop a model to simultaneously measure responses of multiple intertwined 
transcription factors relevant for responses to ROS
Paper III
To identify novel Nrf2-specific drugs in comparison to DMF and evaluate those 
in vitro and in relevant experimental models. 
Paper IV
To assess the role of Nrf2-regulated Gsta4 during OL homeostasis and remyelination.
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4 RESULT AND DISCUSSION
Paper I:
Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis 
is associated with ROS pathways in monocytes
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In Paper I we addressed how DMF affects the oxidative environment in RRMS 
patients prescribed with DMF. 
Based on existing knowledge of DMF we formed the hypothesis that DMF via 
Nrf2 were able to affect the oxidative environment in peripheral blood. We thus 
quantified ROS generation in peripheral monocytes and oxidation of free 8.12-iso-
iPF2α-VI isoprostane in plasma from RRMS patients during their first 6 months 
on Tecfidera therapy. In addition, we sorted CD4+ T cells and CD14+ monocytes 
and assessed transcriptional and epigenetic changes over time. DMF increased 
the oxidative environ ment in peripheral blood, asses by free 8.12-iso-iPF2α-VI 
isoprostane. Patients showing no disease activity during the 24 months of observa-
tion were characterized as responders. Conversely, patients suffering relapses or 
inflammatory activity on MRI were characterized as non-responders. Interestingly, 
only responders were able to increase their number of classical monocytes and this 
difference was prominent already 3 months following therapy start. At this time 
point the monocytes from responders were also capable of generating more ROS 
upon ex vivo stimulation compared to DMF non-responders, this difference was 
also persisting after 6 months. 
Characterization of DNA methylation changes over time further indicated that epi-
genetic changes occurred earlier in monocytes compared to CD4+ T cells. Notably, 
in our cohort, monocyte numbers seemed to be an early marker segregating  responders 
from non-responders. In contrast, lymphocyte numbers could not distinguish these 
two patients groups despite lowering of T cell number being a hallmark with DMF 
therapy110,111. The epigenetic data also indicated ROS to be involved in several 
pathways that were altered over time, which further supported our initial findings 
on changes in the oxidative environment. We further analyzed single nucleotide 
polymorphisms (SNPs) in a set of components to NADPH oxidases 1–4 expressed 
in at different levels in myeloid derived cells. One SNP in NOX3 (rs6919626) was 
suggestively associated with reduced ROS generation after ex vivo stimulation, 
possibly due to lower transcription of NOX3 in individuals carrying the G allele 
at rs6919626. Importantly, SNP rs6919626 was also significantly associated with 
being a non-responder to DMF in terms of clinical effect.
In summary, the generation of ROS in various immune cells is involved in regula-
tion of autoimmune responses. This study builds on and extends a substantial body 
of pre-clinical evidence on how monocytes adapt to their endogenous ROS genera-
tion229 and the central role of monocyte/macrophage-derived ROS on T cells39,64,65,70,76. 
Importantly, our findings in this study are the first to connect the capacity for oxidative 
responses to treatment responses in patients with RRMS. However, it should be noted 
that CNS-infiltrating monocytes are known to contribute to EAE progression60, and 
the most abundant cell types in MS lesions are monocyte derived macro phages and 
microglia with damages due to ROS being evident in MS lesions230. Thus, the role of 
ROS for regulation of adaptive immunity and local target tissue responses may differ. 
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Paper II:
Cross-talk in HEK293 cells between Nrf2, HIF, and NF-κB activities upon  challenges 
with redox therapeutics characterized with single-cell resolution
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In Paper II our group assisted in the development of a novel method to detect tran-
scription factor activity, namely plasmids for transcription factor reporter activation 
based upon fluorescence (pTRAF) in human embryonic kidney cells (HEK293). 
The activity of multiple transcription factors are intertwined during redox regula-
tion. In this study, we developed and described a tool to study cross-talk between 
Nrf2, NFκB and hypoxia inducible factor (HIF) in real-time at the single-cell level 
and in a high throughput manner. As discussed in section 1.2, Nrf2 regulates a 
plethora of transcripts involved in responses to oxidative stress. Upon activation, 
Nrf2 is relocated to the nucleus, promoting transcription via binding to ARE in 
target gene promoter regions (Fig.1). HIF is made up by heterodimers of HIFα 
and HIFβ subunits and promotes transcription in response to hypoxia. NFκB is a 
complex of subunits that initiates inflammatory and cellular responses to  various 
cytokines and stressors. IκB keeps NF-κB in the cytosol, but if phosphorylated, 
NF-κB is released and able to relocate to the nucleus. Based on previously estab-
lished gene binding regions of the three transcription factors231,232, vectors expressing 
lucP2 upon binding of Nrf2, HIF or NF-κB in a Luciferase assay were generated 
and verified to bind the respective transcription factor. Following this, a single 
vector containing all binding regions followed by sequences for mCherry (Nrf2), 
YPet (HIF) or CFP (NF-κB), respectively, were generated.
Upon transfection of HEK293 cells with pTRAF, transcription factor binding gen-
erated a fluorescent signal, and the factual generation of transcripts corresponding 
to Nrf2/HIF/NF-κB activity was confirmed with quantitative polymerase chain 
reaction (qPCR). This included GCLM and HMOX1 (Nrf2), HIF1A and VEGF 
(HIF), and IL8 (NF-κB). Based on the feature of simultaneous Nrf2/HIF/NF-κB-
response with single-cell resolution, cells following transfection were quantified 
and sorted using flow cytometry. In addition, analyses in Paper II were done using 
Operetta high-content imaging allowing for high-throughput analysis of Nrf2/HIF/
NF-κB-responses to various stimulations. 
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Paper III:
Novel vinyl sulfone compounds are more specific Nrf2 activators in vitro and 
in the central nervous system than dimethyl fumarate
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In Paper III we evaluated DMF together with additional newly synthetized Nrf2 
activating compounds based on their activity towards Nrf2 and other transcription 
factors described to be affected by DMF.
Based on previous publications, we formed the hypothesis that addition of  certain 
chemical moieties would improve Nrf2 specificity and improve stability and  passage 
over the BBB233–238. We thus evaluated DMF together with eight de novo synthetized 
vinyl sulfone compounds CH-1 – CH-8 based on cell viability and ability to activate 
Nrf2. CH-1 – CH-3 were the most promising candidates and were further evalu-
ated based on their activity towards NFκB and HIF, which has been described to 
be affected by DMF114. Both DMF and CH-3 activated Nrf2 but CH-3 showed less 
off-target on NFκB or HIF. This was also verified by quantification of transcripts 
downstream of the three transcription factors. Nrf2 is activated in both microglia 
and OLs upon stimulation with either vinyl sulfone239,240 or DMF104. Thus, the 
transcriptional profile was evaluated in these cell-types following CH-3 or DMF. 
Nrf2, HIF and NFκB as assessed by pTRAF in HEK293 cells, are also key tran-
scription factors in conditions of acute trauma and thus CH-3 and DMF were 
finally evaluated in an experimental TBI model43. CH-3 facilitated more extensive 
transcription of Nrf2-regulated genes in the brain compared to DMF upon oral 
gavage, while DMF induced an immediate drop in GSH levels as reflected by 
Gclm and Gsta4241. Following TBI in combination with oral gavage with vehicle, 
DMF or CH-3, DMF (but not CH-3) lowered systemic CD45+ cells as previously 
reported110,111. In addition, DMF also limited axonal degeneration following TBI 
compared to vehicle. In turn, CH-3 preserved or facilitated proliferation and 
 differentiation of OLs following TBI compared to DMF and vehicle. In summary, 
our findings indicate that CH-3 differ from DMF in its effect towards Nrf2, HIF 
and NFκB and their downstream transcripts and that Nrf2-mediated effects are 
largely responsible for transcriptional changes occurring in OLs.
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Paper IV:
Gsta4 restricts apoptosis to promote differentiation of adult oligodendrocytes via 
Fas/Casp8/Bid-axis during homeostasis and remyelination
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In Paper III we evaluated Nrf2 activating compounds including DMF and CH-3. DMF 
(Tecfidera) is a known inducer of gene transcription downstream of Nrf2103,104.
Previous work in our research group explored the role of Glutathione S-transferase 4α 
(Gsta4) in neuroprotection during acute inflammation in the brain216,217. In addition, Gsta4 
has been a predicted transcript downstream of the transcription factor Nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2)6,242, which is the suggested main target of DMF used 
to treat RRMS100,103,104 (Fig. 1). In Paper IV we investigated the impact of high transitional 
levels of Gsta4 in rat OLs during differentiation and remyelination.
The underlying cause for poor remyelinating capacity of OL in MS is still largely 
unknown. Lack of knowledge in this area severely hampers the development of treat-
ments that enhance remyelination. Due to the relatively high susceptibility of OLs to 
ROS and lipid peroxidation146,160,162,166, which generates 4-HNE, we formed the hypothesis 
that over-expression of the 4-HNE scavenging enzyme Gsta4 could provide a beneficial 
intracellular environment in OLs during differentiation and remyelination. We found 
that both remyelinating drug, clemastine fumarate (CF)210,243,244 and DMF increased Plp 
and Gsta4 transcription, the former in a Gsta4-dependent manner and the latter due to 
nuclear activation of Nrf2. Creation of a transgenic rat with constitutive over-expression 
of Gsta4 (DAGsta4) facilitated faster OL differentiation in vitro compared to wild-type 
(DAWt), a phenotype that was reveres upon Gsta4 knock-down. The faster differentiation 
was verified in vivo as DAGsta4 displayed a drastic reduction in OPC number and early 
OLs, while DAWt and DAGsta4 did not differ in number of mature OLs.
RNA-seq on mRNA from O4+ OLs from the CC indicated the Fas/Caspase-8 pathway and 
bFGF signaling to be reduced in DAGsta4 OLs and likely responsible for the faster differen-
tiation. This was confirmed as stimulation of DAWt OLs with a Fas-antagonist promoted 
differentiation to a similar extent as in DAGsta4. In addition, both Caspase-8 and the down-
stream target and inducer of apoptosis Bid were decreased upon Gsta4 over-expression 
and increased upon knock-down. Furthermore, in a toxin-based demyelination model of 
the CC higher levels of Gsta4 led to faster remyelination. Finally, in the MS-like disease 
model EAE, DAGsta4 animals showed improved clinical severity score and disease duration 
compared to DAWt. When lethally irradiating and transplanting DAWt and DAGsta4 rats with 
identical DAGFP bone marrow, DAGFP→DAGsta4 again showed improved clinical severity 
score and disease duration compared to DAGFP→DAWt. In line with previous experiments, 
DAGFP→DAGsta4 showed lower levels of Caspase-8 in spinal cord but also smaller and 
fewer demyelinated lesions, likely due to improved remyelination seen in DAGsta4.
Pioneering studies identified bFGF to be essential for OL development140,143 and described 
cell-cell interaction as crucial for OL survival135,144. A more recent study underlines the 
vulnerability of OLs during differentiation as they only have a few hours to generate 
myelin141. In summary, our study indicates that newly formed/myelin forming OLs to 
represent a particularly sensitive state during OL maturation and that the OLs resistance 
to apoptosis and/or facilitation of more efficient differentiation can be enhanced via 
over expression of Gsta4. This study also indicates Gsta4 and associated mechanism, 
 including the Fas/Caspase8/Bid-axis, to be highly interesting in context of the mode of 
action of certain remyelination-promoting agents.
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5 FURTHER PERSPECTIVES
Today we have access to a number of highly effective immunomodulating treat-
ments in MS that almost entirely can prevent new bouts of disease and drastically 
improve the long-term prognosis. However, these treatments are most effective in 
the initial phases of MS and many patients in later disease phases suffer continued 
disease worsening. The striking advances in treatment of early RRMS in part depends 
on improved knowledge of underlying disease processes, while the understanding 
of disease mechanisms operating in progressive MS remains poorly defined. MS 
involves the loss of neurons, the replacement of which represents a monumental 
challenge. In contrast, enhancing remyelination by modulating existing OPCs or 
perhaps even OLs could be a more tempting target.
This picture is supported by the observations we made in the included studies. We 
herein show that support to differentiating cells to overcome certain thresholds or 
crossroads during differentiation in rodents is beneficial in MS-like disease  models. Our 
findings indicate the importance of redox processes in overcoming these thresholds 
and this could also be of importance in humans. We further show that redox balance 
is a key-element in additional aspects of MS disease where location and cell type 
is decisive of the outcome. In addition we show that its feasible to identify more 
specific Nrf2 activating drug compared to the currently used drug.
On a personal note, it is a captivating time to study oligodendrocytes. A string of recent 
discoveries have revealed the heterogeneity and plasticity of OL cell lineages during 
maturation137,245. In addition, participation by non-dividing OLs in  remyelination 
in higher species brings a new perspective to the field205,208. In  particular I have 
 identified two fields of high interest that deserve further exploration.
Characterization of temporal metabolic changes during OL maturation. By  tradition, 
metabolism in OLs has been addressed from a nerve cell-perspective, e.g. how OLs 
are able to maintain axonal function and integrity via shuttling of lactate and glucose 
between the cells. However, metabolic fluctuation during different OL maturation 
states is not described. Especially halted maturation in context of demyelinating 
disorders is an intriguing phenomenon. Metabolites, such as lactate, have recently 
been described to also possess epigenetic modulatory features by inducing histone 
modifications; a process termed lactylation246. Since OLs are crucial for axonal lactate 
maintenance the role of OLs also in neural lactylation is an interesting research field. 
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Additional in vivo models of remyelination. Lately and partly due to technical 
advances it has become clear that there are crucial discrepancies in remyelination 
between human and lower species247, with consequences for our interpretation 
of earlier experimental data and to what degree this can be translated to humans. 
Neumann et al. have addressed the interesting question how ageing of adult OLs 
may affect their phenotype132. Nobuta et al. likewise have studied OL death in 
PMD248. Both these studies benefit of their (in comparison) simple set-up to study 
failure of OL maturation. To study OL maturation arrest in alternative models 
could be very useful and could later lay the foundation for applications in other 
diseases, such as MS.
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Cross Talk in HEK293 Cells Between Nrf2, HIF,
and NF-jB Activities upon Challenges with Redox
Therapeutics Characterized with Single-Cell Resolution
Katarina Johansson,1 Marcus Cebula,1,* Olle Rengby,1,{ Kristian Dreij,2 Karl E. Carlstro¨m,3
Kristmundur Sigmundsson,4,{ Fredrik Piehl,3 and Elias S.J. Arne´r1
Abstract
Aim: Many transcription factors with importance in health and disease are redox regulated. However, how their
activities may be intertwined in responses to redox-perturbing stimuli is poorly understood. To enable in-depth
characterization of this aspect, we here developed a methodology for simultaneous determination of nuclear factor
E2-related factor 2 (Nrf2), hypoxia-inducible factor (HIF), and nuclear factor kappa-light-chain-enhancer of
activated B cell (NF-jB) activation at single-cell resolution, using a new tool named pTRAF (plasmid for
transcription factor reporter activation based upon fluorescence). The pTRAF allowed determination of Nrf2, HIF,
and NF-jB activities in a high-resolution and high-throughput manner, and we here assessed how redox thera-
peutics affected the activities of these transcription factors in human embryonic kidney cells (HEK293).
Results: Cross talk was detected between the three signaling pathways upon some types of redox therapeutics,
also by using inducers typically considered specific for Nrf2, such as sulforaphane or auranofin, hypoxia for HIF
activation, or tumor necrosis factor alpha (TNFa) for NF-jB stimulation. Doxorubicin, at low nontoxic doses,
potentiated TNFa-induced activation of NF-jB and HIF, without effects in stand-alone treatment. Stochastic
activation patterns in cell cultures were also considerable upon challenges with several redox stimuli.
Innovation: A novel strategy was here used to study simultaneous activation of Nrf2, HIF, and NF-jB in single
cells. The method can also be adapted for studies of other transcription factors.
Conclusion: The pTRAF provides new opportunities for in-depth studies of transcription factor activities. In
this study, we found that upon challenges of cells with several redox-perturbing conditions, Nrf2, HIF, and NF-
jB are uniquely responsive to separate stimuli, but can also display marked cross talk to each other within
single cells. Antioxid. Redox Signal. 26, 229–246.
Keywords: redox regulation, transcription factors, Nrf2, HIF, NF-jB, pTRAF
Introduction
Several redox-regulated transcription factors arehighly important in both health and disease (3, 4, 28, 42).
However, complex, fast, and transient reactions limit current
knowledge on how redox-responsive transcription factors
may be regulated with regard to each other within the same
cellular context, especially upon challenges to cells by redox-
perturbing conditions. To enable direct analyses of three
distinct transcription factor activities at the same time and
in the same cellular context, we here developed a novel
fluorescence-based tool named pTRAF (plasmid for tran-
scription factor reporter activation based upon fluorescence),
enabling simultaneous analyses of the transcriptional acti-
vation from three separate promoter response elements at
single-cell resolution.
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